IQVIA BIOTECH LTD.

1. IQVIA BIOTECH LTD. 2019-02-04 → present
2. NOVELLA CLINICAL LTD 2009-07-02 → 2019-02-04
3. MATRIX CONTRACT RESEARCH LTD. 1997-01-06 → 2009-07-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.”

Group structure

1. IQVIA BIOTECH LTD. · parent
   1. Q Squared Solutions Holdings Limited 0.4% · United Kingdom · Holding company
   2. Q Squared Solutions S.A. 0.4% · Argentina · Lab
   3. Clinical Lab Minority Shareholder Limited 0.4% · United Kingdom · Lab
   4. Q Squared Solutions Holding B.V. 0.4% · Netherlands · Dormant
   5. Q Squared Solutions B.V. 0.4% · Netherlands · Dormant
   6. Q Squared Solutions Limited 0.4% · United Kingdom · Lab
   7. Q Squared Solutions (Quest) Limited 0.4% · United Kingdom · Dormant
   8. Q Squared Solutions Proprietary Limited 0.4% · South Africa · Lab
   9. Q Squared Solutions China Limited 0.4% · United Kingdom · Dormant
   10. Q Squared Solutions (Beijing) Co. Limited 0.36% · China · Lab
   11. Q Squared Solutions KK 0.4% · Japan · Lab
   12. Q Squared Solutions China (Quest) Limited 0.4% · United Kingdom · Dormant
   13. Q Squared Solutions Pte. Ltd. 0.4% · Singapore · Lab

Significant events

• “During 2024 the company observed a revenue decline compared to the prior year. This decline is attributable to macro-economic dynamics impacting funding for Biotech companies which resulted in a reduction in the number of requests for proposals received by the company for new multi-year clinical trial contracts and termination of small number of contracted projects.”
• “The company paid a £109.80 million dividend to its immediate parent company in 2024 (2023: £nil million).”
• “On 30 October 2024, the company purchased a 4% shareholding in Q Squared Solutions China Limited from IQVIA LTD. upon the issue of 2 £1 shares. This shareholding was then transferred to Q Squared Solutions Holding Limited upon the issue of 4 ordinary £0.0001 shares in that company.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

3

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -29.5%

  £108,865,000 → £76,760,000

• Cash

  —

  Not reported

• Net assets

  -17.1%

  £329,149,000 → £272,707,000

• Employees

  -15.7%

  172 → 145

• Operating profit

  -44.9%

  £43,183,000 → £23,783,000

• Profit before tax

  +18%

  £45,487,000 → £53,684,000

• Wages

  -22.4%

  £10,650,000 → £8,263,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers